Cited by 262Diabetes Treatment and ManagementPharmacovigilance and Adverse Drug ReactionsHeart Failure Treatment and Management

The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.

Thiazolidinediones and Heart Failure

Singh, Sonal, Loke, Yoon K., Furberg, Curt D.·2007·Diabetes Care

DOI 10.2337/dc07-0141

Open this paper in CoChat — free account

Abstract

OBJECTIVE—Thiazolidinediones (TZDs) are known to increase the risk of heart failure in patients with type 2 diabetes. We aimed to evaluate the magnitude of the risk of heart failure with TZDs and classify this adverse effect under the novel dose-time-susceptibility system. RESEARCH DESIGN AND METHODS—Evidence from randomized trials, controlled observational studies, anecdotal case reports, case series, and spontaneous reports in the Canadian Drug Reaction Monitoring Program (CADRMP) was analyzed in a teleo-analysis. RESULTS—A random-effects meta-analysis of three randomized controlled trials showed an odds ratio (OR) of 2.1 (95% CI 1.08–4.08; P = 0.03) for the risk of heart failure in patients randomized to TZDs compared with placebo. Four observational studies revealed an OR of 1.55 (1.33–1.80; P < 0.00001) for heart failure with TZDs. A dose-time-susceptibility analysis of 28 published reports and 214 spontaneous reports from the CADRMP database showed that heart failure was more likely to occur after several months (with median treatment duration of 24 weeks after initiation of therapy). Heart failure equally occurred at high and low doses. The adverse reaction was not limited to the elderly, with 42 of 162 (26%) of the reported cases occurring in patients aged <60 years. CONCLUSIONS—Our teleo-analysis confirms the increased magnitude of the risk of heart failure with TZDs. We estimate the number needed to harm with TZDs to be ∼50 over 2.2 years. Existing guidelines and package inserts may have to be revised to incorporate these risk characteristics of TZDs.

Integrity signals

Registry

Crossref · 10.2337/dc07-0141

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial
(2006) · The Lancet · doi:10.1016/s0140-6736(06)69420-8 · Cited by 1,706
Glycemic Control and Heart Failure Among Adult Patients With Diabetes
Iribarren, C., Karter, A. J., Go, A. S., Ferrara, A. M., Liu, J. Y., Sidney, S., & Selby, J. V. (2001) · Circulation · doi:10.1161/01.cir.103.22.2668 · Cited by 709
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Thiazolidinediones, Metformin, and Outcomes in Older Patients With Diabetes and Heart Failure: An Observational Study
Masoudi, F. A., Inzucchi, S. E., Wang, Y., Havranek, E. P., Foody, J. M., & Krumholz, H. M. (2005) · Circulation · doi:10.1161/01.cir.0000154542.13412.b1 · Cited by 458
Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention
Zhang, H., Zhang, A., Kohan, D. E., Nelson, R. D., Gonzalez, F. J., & Yang, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501744102 · Cited by 314
Joining the DoTS: new approach to classifying adverse drug reactions
Aronson, J. K., & Ferner, R. E. (2003) · BMJ · doi:10.1136/bmj.327.7425.1222 · Cited by 298
A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk Factors
Chiquette, E., Ramı́rez, G., & DeFronzo, R. A. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.19.2097 · Cited by 291
A Comparison of the Effects of Rosiglitazone and Glyburide on Cardiovascular Function and Glycemic Control in Patients With Type 2 Diabetes
Sutton, M. S. J., Rendell, M., Dandona, P., Dole, J., Murphy, K., Patwardhan, R., Patel, J., & Freed, M. I. (2002) · Diabetes Care · doi:10.2337/diacare.25.11.2058 · Cited by 254
Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes
Delea, T. E., Edelsberg, J., Hagiwara, M., Oster, G., & Phillips, L. S. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.2983 · Cited by 216

Show all 31 references

Sorted by citations

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Clinical Update: Cardiovascular Disease in Diabetes Mellitus
Wang, C. C. L., Hess, C. N., Hiatt, W. R., & Goldfine, A. B. (2016) · Circulation · doi:10.1161/circulationaha.116.022194 · Cited by 1,222
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 553
Self-citation
Drugs That May Cause or Exacerbate Heart Failure
Page, R. L., II, O’Bryant, C. L., Cheng, D., Dow, T. J., Ky, B., Stein, C. M., Spencer, A. P., Trupp, R. J., & Lindenfeld, J. M. (2016) · Circulation · doi:10.1161/cir.0000000000000426 · Cited by 495
Bioactive compounds in anti-diabetic plants: from herbal medicine to modern drug discovery
Tran, N., Pham, B., & Le, L. (2020) · Biology · doi:10.3390/biology9090252 · Cited by 553
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database
Tzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., et al. (2009) · BMJ · doi:10.1136/bmj.b4731 · Cited by 444
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Rosenstock, J., Vico, M. L., Wei, L., Salsali, A., & List, J. F. (2012) · Diabetes Care · doi:10.2337/dc11-1693 · Cited by 416
Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes
Lipscombe, L. L., Gomes, T., Lévesque, L. E., Hux, J. E., Juurlink, D. N., & Alter, D. A. (2007) · JAMA · doi:10.1001/jama.298.22.2634 · Cited by 345
Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2007) · Diabetes Care · doi:10.2337/dc08-9016 · Cited by 324
Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., Eldor, R., & Abdul‐Ghani, M. A. (2013) · Diabetes Care · doi:10.2337/dcs13-2011 · Cited by 323
Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy
Gilbert, R. E., & Krum, H. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61402-1 · Cited by 303
A concise review of non-alcoholic fatty liver disease
Than, N. N., & Newsome, P. N. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.001 · Cited by 296
Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes
Hagberg, C. E., Mehlem, A., Falkevall, A., Muhl, L., Fam, B. C., Ortsäter, H., Scotney, P. D., Nyqvist, D., Samén, E., Li, L., et al. (2012) · Nature · doi:10.1038/nature11464 · Cited by 290
Meta-analyses of Adverse Effects Data Derived from Randomised Controlled Trials as Compared to Observational Studies: Methodological Overview
Golder, S., Loke, Y. K., & Bland, M. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1001026 · Cited by 279
Self-citation
Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies
Loke, Y. K., Kwok, C. S., & Singh, S. (2011) · BMJ · doi:10.1136/bmj.d1309 · Cited by 247
Self-citation
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
Dormandy, J., Bhattacharya, M., & van Troostenburg, A. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 227
Thiazolidinediones and Risk of Heart Failure in Patients with or at High Risk of Type 2 Diabetes Mellitus
Hernández, A. V., Usmani, A., Rajamanickam, A., & Moheet, A. A. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11587580-000000000-00000 · Cited by 203
The Diabetic Cardiomyopathy: The Contributing Pathophysiological Mechanisms
Salvatore, T., Pafundi, P. C., Galiero, R., Albanese, G., Di Martino, A., Caturano, A., Vetrano, E., Rinaldi, L., & Sasso, F. C. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.695792 · Cited by 165
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
Antidiabetic and haematological effect of aqueous extract of stem bark of Afzelia africana (Smith) on streptozotocin–induced diabetic Wistar rats
Oyedemi, S. O., Adewusi, E. A., Aiyegoro, O. A., & Da, A. (2011) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/s2221-1691(11)60079-8 · Cited by 154
Inflammatory Concepts of Obesity
Rocha, V. Z., & Folco, E. J. E. (2011) · International Journal of Inflammation · doi:10.4061/2011/529061 · Cited by 140
Youth-onset type 2 diabetes mellitus: an urgent challenge
Bjornstad, P., Chao, L. C., Cree‐Green, M., Dart, A. B., King, M., Looker, H. C., Magliano, D. J., Nadeau, K. J., Pinhas‐Hamiel, O., SHAH, A. S., et al. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00645-1 · Cited by 146
Antidiabetic and antioxidant activities of Toddalia asiatica (L.) Lam. leaves in Streptozotocin induced diabetic rats
Irudayaraj, S. S., Sunil, C., Duraipandiyan, V., & Savarimuthu Ignacimuthu, S. J. (2012) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2012.07.006 · Cited by 128
Cardiovascular Safety, Long‐Term Noncardiovascular Safety, and Efficacy of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Systemic Review and Meta‐Analysis With Trial Sequential Analysis
Zhang, X., Zhu, Q., Chen, Y., Li, X., Chen, F., Huang, J., & Xu, B. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007165 · Cited by 130
The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study
Douglas, I., Evans, S. J. W., Pocock, S., & Smeeth, L. L. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000154 · Cited by 112
Management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R. S., & Zinman, B. (2007) · Diabetologia · doi:10.1007/s00125-007-0873-z · Cited by 110
Dietary plant flavonoids in prevention of obesity and diabetes
Dinda, B., Dinda, M., Roy, A., & Dinda, S. (2019) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2019.08.006 · Cited by 107
Antidiabetic Medications and Polypharmacy
Peron, E. P., Ogbonna, K. C., & Donohoe, K. L. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.08.017 · Cited by 109
Diabetes in Friedreich Ataxia
Cnop, M., Mulder, H., & Igoillo‐Esteve, M. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12216 · Cited by 99
Association Between Thiazolidinedione Treatment and Risk of Macular Edema Among Patients With Type 2 Diabetes
IDRIS, I. R., Warren, G., & Donnelly, R. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.1938 · Cited by 90
Cardiovascular effects of bariatric surgery
Beamish, A. J., Olbers, T., Kelly, A. S., & Inge, T. H. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.162 · Cited by 84
Exercise-associated generation of PPARγ ligands activates PPARγ signaling events and upregulates genes related to lipid metabolism
Thomas, A. W., Davies, N. A., Moir, H. J., Watkeys, L. J., Ruffino, J. S., Isa, S., Butcher, L., Hughes, M. G., Morris, K., & Webb, R. (2011) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00864.2011 · Cited by 81
Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure
Erdmann, E., & Wilcox, R. G. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm529 · Cited by 79
Efficacy and Safety Profile Evaluation of Acarbose Alone and in Association With Other Antidiabetic Drugs: A Systematic Review
Derosa, G., & Maffioli, P. (2012) · Clinical Therapeutics · doi:10.1016/j.clinthera.2012.04.012 · Cited by 76
Peroxisome Proliferator-Activated Receptors and Their Agonists in Nonalcoholic Fatty Liver Disease
Choudhary, N. S., Kumar, N., & Duseja, A. K. (2019) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2019.06.004 · Cited by 75
An aPPARent functional consequence in skeletal muscle physiology via peroxisome proliferator-activated receptors
Phua, W. W. T., Wong, M. X. Y., Liao, Z., & Tan, N. S. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051425 · Cited by 72
The risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studies
Varas‐Lorenzo, C., Margulis, A. V., Pladevall, M., Riera‐Guàrdia, N., Calingaert, B., Hazell, L., Romio, S., & Perez‐Gutthann, S. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-129 · Cited by 67
The controversial effects of thiazolidinediones on cardiovascular morbidity and mortality
Stafylas, P. C., Sarafidis, P. A., & Lasaridis, A. N. (2008) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.06.005 · Cited by 64
Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions
Holstein, A., & Beil, W. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250902806424 · Cited by 62
α-Mangostin Mediated Pharmacological Modulation of Hepatic Carbohydrate Metabolism in Diabetes Induced Wistar Rat
Kumar, V., Bhatt, P. C., Kaithwas, G., Rashid, M., Al-Abbasi, F. A., Khan, J. A., Anwar, F., & Verma, A. (2016) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1016/j.bjbas.2016.07.001 · Cited by 60
Rosiglitazone Causes Cardiotoxicity via Peroxisome Proliferator-Activated Receptor γ-Independent Mitochondrial Oxidative Stress in Mouse Hearts
He, H., Tao, H., Xiong, H., Duan, S. Z., McGowan, F. X. J., Mortensen, R. M., & Balschi, J. A. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu015 · Cited by 59
Discovery and development of selective PPARγ modulators as safe and effective antidiabetic agents
Doshi, L. S., Brahma, M. K., Bahirat, U. A., Dixit, A. V., & Nemmani, K. V. S. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003640169 · Cited by 59
Complications of Diabetes Therapy
Corathers, S. D., Peavie, S., & Salehi, M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.005 · Cited by 58
GPR40: A therapeutic target for mediating insulin secretion
FENG, X.-T., LENG, J., XIE, Z., LI, S.-L., ZHAO, W., & TANG, Q.-L. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1142 · Cited by 54
The safety of thiazolidinediones
Tolman, K. G. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2011.534982 · Cited by 54
Antihyperglycemic Effects and Mode of Actions of Musa paradisiaca Leaf and Fruit Peel Hydroethanolic Extracts in Nicotinamide/Streptozotocin‐Induced Diabetic Rats
Aziz, S. M. A., Ahmed, O. M., El-Twab, S. M. A., Al-Muzafar, H. M., Amin, K. A., & Abdel‐Gabbar, M. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/9276343 · Cited by 61
Terpenoids as potential phytoconstituent in the treatment of diabetes: From preclinical to clinical advancement
Roy, S., Ghosh, A., Majie, A., Karmakar, V., Das, S., Dinda, S. C., Bose, A., & Gorain, B. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155638 · Cited by 58
Role of thiazolidinediones, insulin sensitizers, in non‐alcoholic fatty liver disease
Chang, E., Park, C., & Park, S. W. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12107 · Cited by 52
CYP2C metabolism of oral antidiabetic drugs - impact on pharmacokinetics, drug interactions and pharmacogenetic aspects
Holstein, A., Beil, W., & Kovacs, P. L. (2012) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2012.722619 · Cited by 50
Sodium-glucose cotransporter-2 inhibitors and genital and urinary tract infections in type 2 diabetes
Arakaki, R. F. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1167570 · Cited by 52
Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources
Loke, Y. K., Golder, S. P., & Vandenbroucke, J. P. (2011) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098611401129 · Cited by 49
Self-citation
Long-term use of thiazolidinediones and the associated risk of pneumonia or lower respiratory tract infection: systematic review and meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2011) · Thorax · doi:10.1136/thx.2010.152777 · Cited by 46
Self-citation
The cardiovascular safety of incretin-based therapies: a review of the evidence
Petrie, J. R. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-130 · Cited by 47
Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial
Inzucchi, S. E., Khunti, K., FITCHETT, D. H., Wanner, C., Mattheus, M., George, J. T., Ofstad, A. P., & Zinman, B. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa321 · Cited by 47
Effects of Antidiabetic and Antihyperlipidemic Agents on C-Reactive Protein
Dandona, P. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.3.333 · Cited by 42
Effects of sitagliptin beyond glycemic control: focus on quality of life
Sakamoto, Y., Oyama, J., Ikeda, H., Kuroki, S., Gondo, S., Iwamoto, T., Uchida, Y., Kodama, K., Atsushi, H., Shimomura, M., et al. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-35 · Cited by 43
Adapting Medication for Type 2 Diabetes to a Low Carbohydrate Diet
Cucuzzella, M. T., Riley, K., & Isaacs, D. M. (2021) · Frontiers in Nutrition · doi:10.3389/fnut.2021.688540 · Cited by 42
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Spectrum · doi:10.2337/diaspect.22.1.6 · Cited by 40
Pioglitazone has a dubious bladder cancer risk but an undoubted cardiovascular benefit
Ryder, R. E. J. (2014) · Diabetic Medicine · doi:10.1111/dme.12627 · Cited by 37
Comparing Time to Adverse Drug Reaction Signals in a Spontaneous Reporting Database and a Claims Database: A Case Study of Rofecoxib-Induced Myocardial Infarction and Rosiglitazone-Induced Heart Failure Signals in Australia
Wahab, I. A., Pratt, N. L., Ellett, L. M. K., & Roughead, E. E. (2013) · Drug Safety · doi:10.1007/s40264-013-0124-9 · Cited by 38
Synergistic Effect of Cyanidin and PPAR Agonist against Nonalcoholic Steatohepatitis-Mediated Oxidative Stress-Induced Cytotoxicity through MAPK and Nrf2 Transduction Pathways
Shih, P., Hwang, S.-L., Yeh, C., & Yen, G. (2012) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf300005v · Cited by 36
Concomitant therapy with pioglitazone and insulin for the treatment of type 2 diabetes
Yamanouchi, T. (2010) · Vascular Health and Risk Management · doi:10.2147/vhrm.s5838 · Cited by 36
Pleiotropic Effects of Thiazolidinediones: Implications for the Treatment of Patients With Type 2 Diabetes Mellitus
DeFronzo, R. A., Mehta, R. J., & Schnure, J. J. (2013) · Hospital Practice · doi:10.3810/hp.2013.04.1062 · Cited by 35
Careful use to minimize adverse events of oral antidiabetic medications in the elderly
Scheen, A. J. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1912735 · Cited by 34
Anti-diabetic and haematological effects of n-butanol fraction of Alchornea cordifolia leaf extract in streptozotocin-induced diabetic wistar rats.
Mohammed, R. K., Ibrahim, S., Atawodi, S. E.-O., Eze, E. D., Suleiman, J. B., Nnaemeka, U. M., & Malgwi, I. S. (2013) · Scientific Journal of Animal Science · doi:10.14196/sjbs.v2i3.590 · Cited by 34
Review article: Diabetes mellitus and heart failure — an overview of epidemiology and management
Baliga, V., & Sapsford, R. J. (2009) · Diabetes and Vascular Disease Research · doi:10.1177/1479164109338773 · Cited by 40
Poor Glycemic Control Is Associated With Increased Extracellular Volume Fraction in Diabetes
AlBadri, A., Hashmath, Z., Oldland, G., Miller, R., Javaid, K., Syed, A. A., Ansari, B. A., Gaddam, S., Witschey, W. R. T., Akers, S. R., et al. (2018) · Diabetes Care · doi:10.2337/dc18-0324 · Cited by 33
PPARγ attenuates hepatic inflammation and oxidative stress of non‑alcoholic steatohepatitis via modulating the miR‑21‑5p/SFRP5 pathway
Zhang, X., Deng, F., Zhang, Y., Zhang, X., Chen, J., & Jiang, Y. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12463 · Cited by 33
Alternative Medicine in Diabetes - Role of Angiogenesis, Oxidative Stress, and Chronic Inflammation
El‐Refaei, M. F., Abduljawad, S. H., & Alghamdi, A. (2014) · The Review of Diabetic Studies · doi:10.1900/rds.2014.11.231 · Cited by 33
Palliative and end of life care of people with diabetes: issues, challenges and strategies
Dunning, T., & Martin, P. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.09.018 · Cited by 32
Thiazolidinediones and clinical outcomes in type 2 diabetes
Retnakaran, R. R., & Zinman, B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61029-1 · Cited by 31
Youth-onset Type 2 Diabetes: An Overview of Pathophysiology, Prognosis, Prevention and Management
Titmuss, A., Korula, S., Wicklow, B. A., & Nadeau, K. J. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01546-2 · Cited by 42
Drug-induced heart failure
Maxwell, C. B., & Jenkins, A. T. (2011) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100637 · Cited by 31
Thiazolidinedione as a Promising Medicinal Scaffold for the Treatment of Type 2 Diabetes
Singh, G., Kumar, R., Desna, D. S., Chaudhary, M., Kaur, C., & Khurana, N. (2023) · Current Diabetes Reviews · doi:10.2174/0115733998254798231005095627 · Cited by 34
Comparative outcomes of heart failure among existent classes of anti-diabetic agents: a network meta-analysis of 171,253 participants from 91 randomized controlled trials
Yang, D.-Y. D., He, X., Liang, H., Zhang, S., Zhong, X., Luo, C., Du, Z., He, J., Zhuang, X., & Liao, X. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0853-x · Cited by 29
Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism
Iqbal, F., Baker, W. S., Khan, M. I., Thukuntla, S., McKinney, K. H., Abate, N. I., & Tuvdendorj, D. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13743 · Cited by 32
Suppressors of cytokine signaling (SOCS) and type 2 diabetes
Feng, X., Tang, H., Leng, J., & Jiang, Q. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3079-8 · Cited by 28
Prevention of Weight Gain in Adult Patients With Type 2 Diabetes Treated With Pioglitazone
Kushner, R. F., & Sujak, M. (2009) · Obesity · doi:10.1038/oby.2008.651 · Cited by 28
Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Clinical Diabetes · doi:10.2337/diaclin.27.1.4 · Cited by 29
Youth-Onset Type 2 Diabetes: What We’ve Learned From Key Youth-Onset Type 2 Diabetes Studies, What We Still Don’t Know, and Why It Is Important
Nadeau, K. J., Mayer‐Davis, E. J., Gubitosi‐Klug, R., Zeitler, P. S., Kahn, S. E., Dabelea, D., & SEARCH, T. (2025) · Diabetes Care · doi:10.2337/dc25-0001 · Cited by 35
In support of an early polypharmacy approach to the treatment of type 2 diabetes
Wright, E. E., Stonehouse, A. H., & Cuddihy, R. M. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01255.x · Cited by 27
Pleiotropic effects of anti-diabetic drugs: A comprehensive review
Nath, M., Bhattacharjee, K., & Choudhury, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173349 · Cited by 33
Optimal Glycaemic Control in Elderly People with Type 2 Diabetes: What Does the Evidence Say?
Mathur, S., Zammitt, N. N., & Frier, B. M. (2014) · Drug Safety · doi:10.1007/s40264-014-0247-7 · Cited by 29
Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes
Dorkhan, M., Dencker, M., Stagmo, M., & Groop, L. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-15 · Cited by 27
Update on Safety Issues Related to Antihyperglycemic Therapy
Carpio, G., & Fonseca, V. A. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.2.92 · Cited by 27
Rosiglitazone inhibits Kv4.3 potassium channels by open‐channel block and acceleration of closed‐state inactivation
Jeong, I., Bh, C., & Hahn, S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01210.x · Cited by 26
Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly
Jugdutt, B. I. (2010) · Clinical Interventions in Aging · doi:10.2147/cia.s6709 · Cited by 26
Rosiglitazone: can meta-analysis accurately estimate excess cardiovascular risk given the available data? Re-analysis of randomized trials using various methodologic approaches
Friedrich, J. O., Beyene, J., & Adhikari, N. K. J. (2009) · BMC Research Notes · doi:10.1186/1756-0500-2-5 · Cited by 26
Role of Peroxisome Proliferator-Activated Receptor-γin Vascular Inflammation
Ohshima, K., Mogi, M., & Horiuchi, M. (2012) · International Journal of Vascular Medicine · doi:10.1155/2012/508416 · Cited by 26
Perioperative Care of the Geriatric Patient with Diabetes or Hyperglycemia
Maynard, G., O’Malley, C. W., & Kirsh, S. R. (2008) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2008.06.003 · Cited by 22
Novel therapeutics and targets for the treatment of diabetes
Aicher, T. D., Boyd, S. A., McVean, M., & Celeste, A. J. (2010) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.10.1 · Cited by 21
Cardiovascular and microvascular outcomes of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled cardiovascular outcome trials with trial sequential analysis
Zhang, X., Shao, F., Zhu, L., Ze, Y., Zhu, D., & Bi, Y. (2018) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-018-0246-x · Cited by 26
MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism
Kim, S.-H., Hong, S. H., Park, Y., Sung, J.-H., Suh, W., Lee, K. W., Jung, K., Lim, C., Kim, J.-H., Kim, H., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-38281-0 · Cited by 23
Effect of Pretreatment With Pioglitazone on Reperfusion Injury in Diabetic Patients With Acute Myocardial Infarction
Kataoka, Y., Yagi, N., Kokubu, N., Kasahara, Y., Abe, M., & Otsuka, Y. (2011) · Circulation Journal · doi:10.1253/circj.cj-11-0098 · Cited by 22
Pioglitazone: beyond glucose control
de Pablos-Velasco, P. L. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.98 · Cited by 22
Preventing Unnecessary Costs of Drug-Induced Hypoglycemia in Older Adults with Type 2 Diabetes in the United States and Canada
Boulin, M., Diaby, V., & Tannenbaum, C. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162951 · Cited by 21
Validation of an algorithm to identify heart failure hospitalisations in patients with diabetes within the veterans health administration
Presley, C. A., Min, J. Y., Chipman, J., Greevy, R. A., Grijalva, C. G., Griffin, M. R., & Roumie, C. L. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020455 · Cited by 21
Remodeling adipose tissue inflammasome for type 2 diabetes mellitus treatment: Current perspective and translational strategies
Banerjee, A., & Singh, J. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10150 · Cited by 20

Authors: Singh, S., Loke, Y. K., & Furberg, C. D.
Affiliations: Atrium Health Wake Forest Baptist (US)
University of East Anglia (GB)
Wake Forest University Health Sciences (US)
ORCID: Singh, Sonal
Loke, Yoon K.
Venue: Diabetes Care
Publisher: American Diabetes Association
Published: 2007-08-01
Volume: 30
Issue: 8
Pages: 2148-2153
ISSN: 0149-5992 (ISSN-L)
1935-5548
DOI: 10.2337/dc07-0141
OpenAlex: W1979369530
Cited by: 262
References: 31
Citations by year: 2026: 3 · 2025: 4 · 2024: 11 · 2023: 9 · 2022: 9 · 2021: 12 · 2020: 13 · 2019: 11 · 2018: 11 · 2017: 6 · 2016: 12 · 2015: 14 · 2014: 15 · 2013: 19 · 2012: 18
FWCI: 3.47
Type: journal article
Language: en
Open access: closed
Locations: Diabetes Care (publishedVersion)
PubMed (publishedVersion)
UEA Digital Repository (University of East Anglia) (submittedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
Keywords: thiazolidinediones, heart failure, type 2 diabetes, adverse drug reactions, number needed to harm, drug safety, spontaneous adverse drug reports, drug labeling revision
MeSH terms: Diabetes Mellitus, Type 2, Diabetic Angiopathies, Disease Susceptibility, Heart Failure, Humans, Hypoglycemic Agents, Odds Ratio, Randomized Controlled Trials as Topic, Thiazolidinediones

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Thiazolidinediones and Heart Failure

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks